Home ›
Diffuse Large B-Cell (DLBCL) Lymphoma Trials ›
NCT07451652
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Trial Details
NCT ID NCT07451652
Phase PHASE2
Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Status RECRUITING
Cancer Type Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions Epcoritamab Gemcitabine (1000 mg/m2) Oxaliplatin
Locations (sample) Monterrey, Nuevo León, Mexico|25.68435,-100.31721
Key Eligibility Criteria
Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to … Women of reproductive age who agree on getting a contraceptive method Subjects who fulfill Lugano´s criteria for disease activity Subjects who voluntarily accept to participate in this study
For full eligibility, visit ClinicalTrials.gov .